Competing interests
Cancer, Autism
SIMONS, CANCER
KA was supported by a NHMRC Career Development Fellowship (1141207) and a University of Melbourne Dame Kate Campbell Fellowship. KA has received funding from the NHMRC, MRFF and Wellcome Trust—all unrelated to this work. MB is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131). MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier—all unrelated to this work. ADT has received honoraria for lectures for Otsuka Pty, Janssen and Janssen and Servier and has served on an advisory board for Servier—all unrelated to this work. BN is supported by a NHMRC Senior Research Fellowship (1137687) and a University of Melbourne Dame Kate Campbell Fellowship—all unrelated to this work. MA-J was supported by an Investigator Grant (APP1177235) from the NHMRC and a Dame Kate Campbell Fellowship from The University of Melbourne—all unrelated to this work. CP was supported by a NHMRC Senior Principal Research Fellowship (1105825), and NHMRC L3 Investigator Grant (1196508). Over the past three years, CP has received funding from NHMRC, Lundbeck Foundation, MRFF, and has received honoraria for talks at educational meetings and as a member of an advisory board for Lundbeck, Australia Pty Ltd—all unrelated to this work. The other authors report no biomedical financial interests or potential conflicts of interest.